F. Lavie

机构：Johnson & Johnson (France) · ORCID：0000-0002-5213-257X

发表论文 93 篇 · 总被引 849 次 · h-index 16

代表论文

• Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling (2025 · Frontiers in Immunology · 被引 33)
• Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study (2022 · Annals of the Rheumatic Diseases · 被引 25)
• Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study (2022 · Annals of the Rheumatic Diseases · 被引 23)
• Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data (2023 · Lara D. Veeken · 被引 21)
• Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST (2023 · Alimentary Pharmacology & Therapeutics · 被引 16)
• Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis (2023 · RMD Open · 被引 13)